UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
SCHEDULE 13G
 
(Rule 13d-102)
 
Information Statement Pursuant to Rules 13d-1 and 13d-2
 
Under the Securities Exchange Act of 1934
 
(Amendment No.      )*
 

 
CELLULAR BIOMEDICINE GROUP, INC.
(Name of Issuer)

Common Stock, $0.001 par value per share
(Title of Class of Securities)

276050101
(CUSIP Number)

 
June 25, 2014
 
Date of Event Which Requires Filing of the Statement
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
 
Rule 13d-1(b)
   
T
Rule 13d-1(c)
   
 
Rule 13d-1(d)

 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
 The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 
 

 


 

 
Cusip No.   276050101
13G
Page 2 of 5 Pages

 
1
NAMES OF REPORTING PERSONS: Mission Right Limited
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): N/A (1)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)     o
(b)     T
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
 
 
NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING PERSON
WITH
5
SOLE VOTING POWER
746,268
6
SHARED VOTING POWER
  -0-
7
SOLE DISPOSITIVE POWER
746,268
8
SHARED DISPOSITIVE POWER
-0-
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
746,268
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES                      o
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.2% (2)
12
TYPE OF REPORTING PERSON
CO
__________
 
(1)   Mission Right Limited is incorporated in the British Virgin Islands and does not have an I.R.S. Identification Number.
 
(2)   Based on 9,073,368 shares of common stock of the Issuer outstanding derived from (i) 7,580,831 shares of Common Stock outstanding as of July 1, 2014, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2014 plus (ii) those shares issued in the Issuer’s recently completed private placement of 1,492,537 as disclosed in the Issuer’s Form 8-K filed June 23, 2014.
 

 
 

 
 
Cusip No.   276050101
13G
Page 3 of 5 Pages

Item 1(a)
Name of Issuer
   
Cellular Biomedicine Group, Inc.
 
Item 1(b)
Address of Issuer’s Principal Executive Offices
   
530 University Avenue, #17, Palo Alto, California 94301
 
Item 2(a)
Name of Person Filing

This Schedule 13G is being filed by Mission Right Limited (“Mission Right”) with respect to shares of common stock of the above-named issuer owned by Mission Right.
 
The filing of this statement shall not be construed as an admission that any of the Reporting Person is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
 
Item 2(b)
Address of Principal Business Office

The address of the principal business office of each of the Reporting Persons is 4503-5, 45/F, China Resources Building, 25 Harbour Road, Wanchai, Hong Kong.
 
Item 2(c)
Citizenship

Mission Right is a corporation organized under the laws of the British Virgin Islands.
 
Item 2(d)
Title of Class of Securities

Common stock, $0.001 par value
 
Item 2(e)
CUSIP Number

276050101
 
Item 3
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
                   
(a)
Broker or dealer registered under Section 15 of the Exchange Act;
   
(b)
Bank as defined in Section 3(a)(6) of the Exchange Act;
   
(c)
Insurance company as defined in Section 3(a)(19) of the Exchange Act;
   
(d)
Investment company registered under Section 8 of the Investment Company Act;
   
(e)
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 
 

 


 
Cusip No.   276050101
13G
Page 4 of 5 Pages

(f)
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
   
(g)
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
   
(h)
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
   
(i)
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
   
(j)
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

Item 4
Ownership

(a)
Mission Right beneficially owns 746,268   shares of Common Stock.
     
(b) The number of shares Mission Right beneficially owns constitutes approximately 8.2% of the Common Stock outstanding.
     
(c)
Number of shares as to which such person has:
 
     
 
(i)
sole power to vote or to direct the vote:  746,268
     
 
(ii)
shared power to vote or to direct the vote:  0
     
 
(iii)
sole power to dispose or to direct the disposition of:  746,268
     
 
(iv)
shared power to dispose or to direct the disposition of:  0


Item 5
Ownership of Five Percent or Less of a Class
                      
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following
 

 
 

 
 
Cusip No.   276050101
13G
Page 5 of 5 Pages

 
 
Item 6 Ownership of More than Five Percent on Behalf of Another Person
 
                      
Not Applicable
 

 
Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
 
                      
Not Applicable
 

 
Item 8 Identification and Classification of Members of the Group
 
                      
Not Applicable
 

 
Item 9 Notice of Dissolution of Group
 
                      
Not Applicable
 

 
Item 10 Certification
 
                      
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 

 
 

 


 
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
 
Dated this 7th day of July, 2014.
 

 
MISSION RIGHT LIMITED
 

 
By:
s Chan Boon Ho Peter
 
Name:    Chan Boon Ho Peter
 
Title:  Director

Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cellular Biomedicine Charts.
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cellular Biomedicine Charts.